Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,058.18
+37.34 (3.66%)
At close: Feb 6, 2026, 4:00 PM EST
1,068.53
+10.35 (0.98%)
After-hours: Feb 6, 2026, 7:59 PM EST
Eli Lilly Market Cap
Eli Lilly has a market cap or net worth of $947.47 billion as of February 6, 2026. Its market cap has increased by 30.19% in one year.
Market Cap
947.47B
Enterprise Value
979.82B
1-Year Change
30.19%
Ranking
Category
Stock Price
$1,058.18
Market Cap Chart
Since December 1, 1998, Eli Lilly's market cap has increased from $99.25B to $947.47B, an increase of 854.65%. That is a compound annual growth rate of 8.65%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 6, 2026 | 1.00T | -1.54% |
| Dec 31, 2025 | 1.02T | 38.63% |
| Dec 31, 2024 | 732.87B | 32.44% |
| Dec 29, 2023 | 553.37B | 59.19% |
| Dec 30, 2022 | 347.61B | 31.56% |
| Dec 31, 2021 | 264.23B | 63.60% |
| Dec 31, 2020 | 161.51B | 27.99% |
| Dec 31, 2019 | 126.19B | 2.94% |
| Dec 31, 2018 | 122.58B | 31.81% |
| Dec 29, 2017 | 93.00B | 14.54% |
| Dec 30, 2016 | 81.20B | -13.04% |
| Dec 31, 2015 | 93.37B | 21.55% |
| Dec 31, 2014 | 76.82B | 33.69% |
| Dec 31, 2013 | 57.46B | 0.39% |
| Dec 31, 2012 | 57.23B | 18.95% |
| Dec 30, 2011 | 48.12B | 19.08% |
| Dec 31, 2010 | 40.41B | -1.52% |
| Dec 31, 2009 | 41.03B | -10.38% |
| Dec 31, 2008 | 45.79B | -24.40% |
| Dec 31, 2007 | 60.56B | 2.72% |
| Dec 29, 2006 | 58.96B | -8.34% |
| Dec 30, 2005 | 64.32B | 0.16% |
| Dec 31, 2004 | 64.22B | -18.68% |
| Dec 31, 2003 | 78.97B | 10.71% |
| Dec 31, 2002 | 71.33B | -19.21% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 578.21B |
| AbbVie | 394.89B |
| Merck & Co. | 302.63B |
| AstraZeneca | 297.70B |
| Novartis AG | 295.04B |
| Novo Nordisk | 207.72B |
| Amgen | 206.95B |
| Gilead Sciences | 189.20B |